Content available at: <https://www.ipinnovative.com/open-access-journals>

IP Indian Journal of Clinical and Experimental Dermatology

Journal homepage: www.ijced.org/

Original Research Article

Observational case studies of the effect of phage laden Ganga water on psoriasis

Ranjana Waghralkar¹, Bharat Jhunjhunwala^{2,*}¹Waghralkar Ayurved Hospital, Anjni Chowk, Nagpur, Maharashtra, India²Dept. of Phage Therapy, Ganga Today Trust Lakshmoli, Maletha, Kirti Nagar, Tehri, Uttarakhand, India

ARTICLE INFO

Article history:

Received 22-06-2021

Accepted 03-08-2021

Available online 04-09-2021

Keywords:

Psoriasis

Phage

Ganga water

dermatological

microbiome

ABSTRACT

Water of Ganga river is reported to have more than 200 isolates of phages. This study has used the naturally available cocktail of phages in the Ganga water as a treatment for chronic Psoriasis. In the conventional Phage Therapy (PT) phages that are active against specific bacteria are first identified; then isolated, multiplied and administered to the patient. We have made a novel innovation of administering the naturally available cocktail of phages in the water of the Ganga river without first identifying the target bacteria and isolating specific phages that may be active against them. In doing so, we enable the large numbers of phages to self-identify the bacteria that are present and act against them. This approach shortcuts the tortuous process of conventional PT. Further, the phages act against a number of bacteria simultaneously and provide good results in psoriasis which has multiple causes.

Patients who took Ganga water for only 2 weeks showed benefit but the benefit did not sustain after stoppage of the treatment and the disease relapsed to the pre-treatment levels. The same patients showed sustained benefit after they took Ganga water for four weeks. Conclusion is that Ganga water can be used for therapeutic purposes as long as the treatment is continued for at least four weeks. The study underscores the need to establish more robust protocol for treatment of dermatological and possibly other diseases with the cocktail of phages available in the waters of the Ganga river.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

A number of dermatological disorders are caused by the microbiome.¹ Scientists have suggested that the anti-microbial action of phages could help treat dermatological disorders.² The exact method of action of the phages may often not be known.³ However, that does not prevent us from undertaking experimental treatment of dermatological disorders by phage therapy (PT). Providing relief to the patient is the primary objective of the medical profession.

PT has been used to treat a number of bacterial infections such as from *Pseudomonas Aeruginosa*,^{4–8} *Staphylococcus Aureus*,^{5–7} *Acinetobacter*,^{6,7} *Enterobacteriaceae*,⁶

Escherichia,⁸ *Klebsiella*,⁷ and *Streptococcus*.⁸ Normally PT uses specific phages to treat specific bacterial infections. However, in the case of dermatological disorders, where possibly a number of bacterial infections are required to be simultaneously treated, a cocktail of phages could be more effective. The use of a cocktail of phages have been made to simultaneously target *S. aureus*, *S. pyogenes*, *P. mirabilis*, *P. vulgaris*, *P. aeruginosa*, and *E. coli* was used.⁸ The use of a cocktail is also preferred because the chances of emergence of phage resistance are reduced.⁶

The established method of making a cocktail of phages is to first isolate a number of phages, multiply them, mix them and then administer them to the patient.^{9,10} This process is expensive and faces the problem of maintaining stability of phages in the cocktail.⁸ We make a novel advance of

* Corresponding author.

E-mail address: bharatji@gmail.com (B. Jhunjhunwala).

administering the naturally available cocktail of phages in the Ganga river. The National Environment Engineering Research Institute, Nagpur has undertaken detailed survey of the presence of phages in the Ganga river. They have found that the water of the upper Ganga river contained more than 200 isolates of phages.¹¹ More specifically, they have reported that phages having bactericidal activity against *Mycobacterium*, *Streptococcus*, *Pseudomonas*, *Yersinia*, *Salmonella*, *Staphylococcus*, *Klebsiella*, *Vibrio*, *Shigella*, *Clostridium*, *Acinetobacter*, *Erwinia*, *Aeromonas*, *Escherichia*, *Cronobacter*, *Enterobacteria*, and *Campylobacter* etc. are found in the Ganga waters. This unparalleled availability of large number of isolates gave us the reason to try treating chronic Psoriasis patients by cocktail phage therapy.

Psoriasis comes under papulosquamous disorder with a morphological feature of scaly papules and plaques. Psoriasis is an autoimmune disorder of the skin results in hyper proliferation of the skin. The itch scraping causes multiple bleeding points. Psoriatic lesions are distributed symmetrically on scalp, elbow, knees, lumbo-sacral area and in folds of body. Genetic factors play important role in its aetiology. There is a 7 percent chance that a person will contract psoriasis if one parent has psoriasis; and chances are 14 percent if both parents have psoriasis.

Type I psoriasis occurs at or before the age of 40 and seen in 75% of patients. Type II Psoriasis presents after the age of 40, with a peak at 55-60 years of age. The course of disease is chronic though periods of complete remission do occur. This is further divided to 3 subtypes. Acute form is characterized by small eruption and is accompanied by slight itching. This form is characteristic of psoriasis in childhood and young adults. Chronic plaque psoriasis with guttate exacerbation is seen in adults wide spread small plaque (< 3 cm) psoriasis. Nail psoriasis has been reported 40-50% of psoriatic patients.

2. Materials and Methods

The water of Ganga river upstream of Rudra Prayag, from where we have collected the same, has Dissolved Oxygen as 9.6 mg/liter and Biological Oxygen Demand at 1.2 mg/liter as per Government Reports. These levels meet the water quality standards for drinking water. The pH is reported to be between 6.5 to 8.5 which too meets the drinking water quality standards. However, the water had coliforms at 9300 per 100 ml against the requirement of less than 50 for drinking water.¹² We tested the water after one month of storage and found that the phages adsorbed in the sediments had cleared the overlaying column of water of coliforms indicating that the water was fit for drinking.

We administered Ganga water orally to 38 patients having chronic psoriasis of two or more years. They were administered Ganga water in addition to the Ayurvedic prescription medicines which the patients had been taking

since previously. All patients were not getting relief from the prescription medicines. The results seen in the present study can be attributed to Ganga water only because the prescription medicines had been continued and PT was added to the same. The patients were informed that they were being given Ganga water and their consent was taken.

Indeed, it cannot be totally precluded that the results reported here could be due to the prolonged use of the prescription medicines. However, that is not likely because they had been using the prescription medicines for more than two years without relief at the time that PT was added.

The protocol for intake was as follows:

1. 10 ml Ganga water twice a day, half hour before meals
2. Avoid taking any hot liquid (tea, coffee, etc.) immediately after consuming Ganga water.

The 1st phase of administration of Ganga water was 2 weeks followed by rest period of 2 weeks.

The 2nd phase of administration was 1 month followed by rest period of 1 month.

All patients having psoriasis were selected for the study.

The study size was determined by the number of psoriasis patients that came to the physician for treatment.

2.1. Inclusion criteria

Suffering from psoriasis, adult.

2.2. Exclusion criteria

Young below 18 years, pregnant, neurosis.

The result was scored on 1 to 10 Likert scale as assessed by the medical practitioner to assess the results,^{13,14} with “5” and less representing a “morbid” situation, and “10” representing best situation.

The results were recorded at 5 points of time:

Fig. 1:

2.2.1. Beginning of treatment

Phase I, Administered: Ganga water was administered. Change before and after administration was recorded.

Table 1: Results at four phases (All figures of “level” n Likert Scale of 1-10).

S. No	Age	Prescribed Medicines	Phase I	Phase II Rest 2 weeks	Phase III Oral intake for 1 month	Phase IV Rest 1 month
1	61yrs	Khadristria Syp 2-2 spoon, kheir 5 gm, sariwa 5 gm, Nagarmotha 5 gm, Bawachi 5 gm, Kamdudha 5 gm, Kanchnar guggulu 5 gm, 30 Pudies- 1-1 days	Patient showed improvement to level 1.5.	Morbidity relapsed to pre-treatment level with no improvement.	Improvement came back to level 1.5.	Patient remains at same level 1.5. No relapse.
2	54 yrs.	Raktashodka syp 2-2 spoon, Cap Atrisor 2-2/ 2 times, Bruhadaltaphal oil	Improvement of level 4-5.	Morbidity relapsed to pre-treatment level with no improvement.	Improved to level 5-6.	Improvement maintained at level 6. No relapse.
3	31 yrs.	Dermatone Syp, Cap. Finbid 1-1 /30, Cap Visora 2-2/60,	Improvement of level 4-5.	Morbidity relapsed to pre-treatment level with no improvement.	Improved to level 5.	Improvement maintained at level 5. No relapse.
4	71 yrs.	Raktashodka Syp 2-2, Tab Kanchnar guggul 2-2/tab 120, Bruhatdantfal oil, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm, Kamdudha 10 gm Kanchnar guggulu 5 gm Gulwelsatwl 10 gm, 60 Pudies- 1-1 days	Patient showed improvement to level 2.	Morbidity relapsed to pre-treatment level with no improvement.	Improvement increased to level 2.5.	Patient maintained at level 2.5.
5	40 yrs.	Tab Kanchnar guggul 2-2/tab 120, Bruhatdantfal oil, Atrisor oint Khadristria syp, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm Bawachi 10 gm, Kamdudha 10 gm , Kanchnar guggul 10 gm, Gulwelsatwl 10 gm. 60 Pudies 1-1/days	Improvement at level 4.	Morbidity relapsed to pre-treatment level with no improvement.	Improved back to level 4 as at the end of Phase I.	No change. Improvement remains at level 4.
6	31 yrs.	Tab Kanchnar guggul 2-2/tab 120, 777 oil Psoralin oint, Dermation syp, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm, Kamdudha 10 gm, Kanchnar guggul 10 gm, Gulwelsatwl 10 gm, 60 Pudies 1-1/days	Patient showed improvement at level 3.	Morbidity did not relapse.	Improvement remained at level 3.	Patient remains at same level 3 of improvement.
7	78 Yrs.	Tab Kanchnar guggul 2-2/tab 120, Psora oil , Trichoden oint, Bactimo syp, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm, Kamdudha 10 gm, Kanchnar gu 10 gm ,Gulwelsatwl 10 gm, 60 Pudies 1-1/days	Patient showed improvement at level 2.	Morbidity relapsed to pre-treatment level.	Improvement is same at level 2.	Improvement remains same at level 2 with no relapse.
8	22 Yrs.	Tab Kanchnar guggul 2-2/tab 120, Raktufi syp, Bruhatdantfal oil, Atrosor oil, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm , Kamdudha 10 gm , Kanchnar guggul 10 gm , Gulwelsatwl 10 gm, 60 Pudies 1-1/days	Improvement at level 5.	Morbidity relapsed to pre-treatment level.	Improvement is same at level 5.	Improvement remains at same level 5 with no relapse.
		Average	3.3	1.2	3.6	3.5
		Median	3.5	1.0	3.5	3.5

Fig. 2:

Phase II, Rest: Ganga water was stopped and change at the end of the rest was recorded.

Phase III, Administered: Ganga water was administered. Change at the end of administration was recorded.

Phase IV, Rest: Status was recorded 4 weeks after stoppage of treatment.

Thirty eight patients were included in the study initially. 18 patients did not take interest in the treatment during Phase I itself leaving 20 patients who completed the treatment in Phase I. Of these, 3 did not continue in phase III because they did not find benefit in Phase I while 5 did not continue in phase III even though they got some benefit in Phase I. This left 12 patients who took Treatment in Phase III. Of these 12 patients, 4 did not cooperate in providing report of the final result after Phase IV. Hence, we report the results of the 8 patients who took treatment in Phase I and III and cooperated in providing the results.

3. Results & Discussion

We present the results both in average and median. Average is calculated by summing the values and dividing by the numbers of observations. This is sensitive to one or few observations showing high numbers. Thus, median is considered to be more robust.¹⁵

The 8 patients showed a median improvement of 2.5 (range from 1 to 3.5) in Phase I of 15 days of administration. The improvement relapsed to original level showing no improvement (from 3.5 to 1) although one patient (Number 6) reported no relapse. A median improvement of 2.5 (from 1 to 3.5) was again recorded in Phase III of 30 days of administration. This improvement held at level 3.5 and did

not relapse at the end of Phase IV of Rest.

Limitations of the study are as follows. One, the confounding effect of normal prescription medicines cannot be precluded though it is not likely because the patients had been suffering from psoriasis for 2 years or more and had been taking the prescription medicines. Two, the sample size was small. However, oftentimes an experimental treatment can open up new vistas.¹⁶ Three, only one protocol was adopted. It is necessary to try different protocols and arrive at the most robust protocol. Four, at the end of Phase IV, four patients reported improvement to level 4-6 while four reported improvement to level 1-3. A longer treatment period needs to be tried to ascertain if greater improvement is obtained.

A limitation of the study is that the exact numbers and species of phages are not identified. Therefore, it is possible that water taken from the Ganga river at another place and time may have a different combination of phages that may or may not be effective for treatment.

4. Conclusion

Conclusion is that Ganga water therapy holds much potential for the treatment of psoriasis if the treatment is made for minimum four weeks.

Acknowledgements

Drs. Narendra Nath Mehrotra, Amitabh Satsangi, Anil Gourishetty, Arvind Pandey, Sukhdev Singh and Surabhi Puri have provided extremely valuable help in conceiving and planning the study.

References

1. Britta DP, Lynda G, Melanie D, Aglaya M, Bernhard P, Chris C, et al. Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. *Microorganisms*. 2021;9(2):353.
2. Andrej G, Paul B, Maciej P, Jan B, Ryszard M, Ewa JM, et al. Perspectives of Phage Therapy in Non-bacterial Infections. *Front Microbiol*. 2018;9:3306. doi:10.3389/fmicb.2018.03306.
3. Prasanth M, Tamhankar A, Sebastian L, Nachimuthu R, Nachimuthu R. Pharmacological and Immunological Aspects of Phage Therapy. *Infect Microbes Dis*. 2019;1(2):34–42.
4. Pires DP, Boas DV, Sillankorva S, Azeredo J. Phage Therapy: a Step Forward in the Treatment of *Pseudomonas aeruginosa* Infections. *J Virology*. 2015;89(15):7449–56. doi:10.1128/JVI.00385-15.
5. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M. Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. *PLoS ONE*. 2009;4(3):4944.
6. Wunderink RG. Turning the Phage on Treatment of Antimicrobial-Resistant Pneumonia. *Am J Respir Crit Care Med*. 2019;200(9). doi:10.1164/rccm.201908-1561ED.
7. Rezai MS, Rahimzadeh G. Phage Therapy to Prevent Nosocomial Bacterial Pneumonia in Patients with Severe COVID-19 in 2020. *Am J Biomed Sci Res*. 2020;10(5). doi:10.34297/AJBSR.2020.10.001563 Abstract.
8. Yoon R, Chang K, Wallin M, Lin Y, Leung SSY, Wang H, et al. Phage Therapy for Respiratory Infections. *Adv Drug Deliv Rev*. 2018;133:76–86. doi:10.1016/j.addr.2018.08.001.

9. Marcin W, Wojewodzic. Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19). *Ther Appl Res*. 2020;1(2):60–5. doi:10.1089/phage.2020.0014.
10. Martinecza A, Wojewodzic MW. Could bacteriophages be the answer to the COVID-19 crisis? *Expert Rev Anti-infective Ther*. 2020;19(5):557–8. doi:10.1080/14787210.2021.1836960.
11. National Environment Research Institute, Ganga Study; 2018. Available from: <https://nmcg.nic.in/writereaddata/fileupload/NMCGNEERI%20Ganga%20Report.pdf>.
12. Central Pollution Control Board, Pollution Assessment: River Ganga; 2103. Available from: <https://cpcb.nic.in/wqm/pollution-assessment-ganga-2013.pdf>.
13. Versta Research, How to Label Your 10-Point Scale. Available from: <https://verstaresearch.com/blog/how-to-label-your-10-point-scale/>.
14. Decker F. How to Interpret Likert Surveys, Sciencing, March 2018. Available from: <http://sciencing.com/interpret-likert-surveys-8573143.html>.
15. Cook JD. Example of efficiency for mean vs. median; 2009. Available from: <http://www.johndcook.com/blog/2009/03/06/student-t-distribution-mean-median/>.
16. Truog RD. The UK sets limits on experimental treatments. *JAMA*. 2017;318(11):1001–2. doi:10.1001/jama.2017.10410.

Author biography

Ranjana Waghralkar, Medical Practitioner

Bharat Jhunjhunwala, Trustee <https://orcid.org/0000-0002-2121-6519>

Cite this article: Waghralkar R, Jhunjhunwala B. Observational case studies of the effect of phage laden Ganga water on psoriasis. *IP Indian J Clin Exp Dermatol* 2021;7(3):186-190.